NCT03838263View on ClinicalTrials.gov

Feasibility and Tolerance of Nivolumab Neoadjuvant Immunotherapy in High Risk HPV Driven Oropharynx Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

July 25, 2019

Primary Completion Date

April 1, 2022

Study Completion Date

November 20, 2024

Conditions
Oropharynx Cancer
Interventions
DRUG

Nivolumab

2 nivolumab infusion (240 mg IV) 2 weeks apart (on day 1 and day 15) followed by standard chemoradiation.

RADIATION

Chemoradiation

Standard of Care chemoradiation for 7 weeks (70 Gray delivered to the tumor by IMRT) with high-dose cisplatin (100mg/m2) at week 1, 4 and 7

Trial Locations (11)

54519

Institut de cancerologie de Lorraine Alexis Vautrin, Vandœuvre-lès-Nancy

69373

Centre Léon Bérard, Lyon

75005

Institut Curie, Paris

75015

Hopital Europeen Georges Pompidou, Paris

75970

Hopital Tenon, Paris

76038

Centre Henri Becquerel, Rouen

84918

Institut Sainte Catherine, Avignon

92100

Hopital Beaujon, Clichy

92150

Hopital Foch, Suresnes

94805

Institut Gustave Roussy, Villejuif

06189

Centre Antoine Lacassagne, Nice

All Listed Sponsors
lead

UNICANCER

OTHER

NCT03838263 - Feasibility and Tolerance of Nivolumab Neoadjuvant Immunotherapy in High Risk HPV Driven Oropharynx Cancer | Biotech Hunter | Biotech Hunter